January 2009 Volume 27 Number 1, pp 1 - 100
Visit Nature Biotechnology online to browse the journal.
Now available at http://links.ealert.nature.com/ctt?kn=54&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access to Nature Biotechnology online. To purchase a subscription, please visit:
http://links.ealert.nature.com/ctt?kn=32&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=42&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
Bioentrepreneur: an online resource for budding business in the life sciences.
http://links.ealert.nature.com/ctt?kn=3&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
miRCURY LNA(TM) PCR
Your fast track to microRNA discovery
The success of our LNA-based microRNA real-time PCR products continues.
The secret? See how we compare to other leading brands, here
http://links.ealert.nature.com/ctt?kn=45&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
We now have more than 500 assays - learn more now.
http://links.ealert.nature.com/ctt?kn=53&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
=====================================================================
=========================== ADVERTISEMENT ===========================
BIOPARTNERING
Visit our Biopartnering site to view Company Profiles and Partnership Opportunities:
=====================================================================
=========================== ADVERTISEMENT ===========================
Naturejobs presents a Focus on Biotech/Pharma
Nature issue date: 22 January 2009
Deadline for advertisers:
US 15 January 2009
UK/ROW 16 January 2009
Advertise your biotechnology and pharmaceutical career opportunities, courses and events in front of readers interested in these scientific fields. For more information on this feature or to advertise, contact your Naturejobs representative at www.nature.com/naturejobs/about-us/contact-rep.html or email naturejobs@nature.com.
Each job advertisement receives a complimentary 60 day posting on http://links.ealert.nature.com/ctt?kn=56&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
=====================================================================
=========================== ADVERTISEMENT ===========================
SciBX - now available in HTML format
SciBX: Science-Business eXchange is a weekly publication that identifies and analyses the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Subscribe to SciBX and you won't miss the next big thing.
SciBX is now available in full-text, HTML format on the nature.com platform. Recommend SciBX to your library today.
For more information visit: http://links.ealert.nature.com/ctt?kn=102&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
=====================================================================
----------------------
EDITORIAL
----------------------
Begging bowls p1
The biotech sector needs government support, not blank checks.
doi:10.1038/nbt0109-1
http://links.ealert.nature.com/ctt?kn=113&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
----------------------
NEWS
----------------------
Biotech sector ponders potential 'bloodbath' pp3 - 5
Peter Mitchell
doi:10.1038/nbt0109-3
http://links.ealert.nature.com/ctt?kn=64&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
Plant genomics land big prizes p5
Emily Waltz
doi:10.1038/nbt0109-5
http://links.ealert.nature.com/ctt?kn=99&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
Buzz around Campath proof-of-concept trial in MS pp6 - 8
Randy Osborne
doi:10.1038/nbt0109-6
http://links.ealert.nature.com/ctt?kn=121&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
Myriad wins BRCA1 row p8
Nayanah Siva
doi:10.1038/nbt0109-8a
http://links.ealert.nature.com/ctt?kn=10&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
Value-driven price deal p8
Susan Aldridge
doi:10.1038/nbt0109-8b
http://links.ealert.nature.com/ctt?kn=36&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
Doubts surround link between Bt cotton failure and farmer suicide pp9 - 10
Cormac Sheridan
doi:10.1038/nbt0109-9
http://links.ealert.nature.com/ctt?kn=48&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
EU tightens animal rules p10
Hayley Birch
doi:10.1038/nbt0109-10a
http://links.ealert.nature.com/ctt?kn=114&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
Public life cut short p10
Victor Bethencourt
doi:10.1038/nbt0109-10b
http://links.ealert.nature.com/ctt?kn=44&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
Pfizer's $100 million stem cell stake p10
Nayanah Siva
doi:10.1038/nbt0109-10c
http://links.ealert.nature.com/ctt?kn=23&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
JAMA study casts cloud over biologic safety pp11 - 12
Jim Kling
doi:10.1038/nbt0109-11
http://links.ealert.nature.com/ctt?kn=40&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
PROFILE
Mark Roth p13
Mark Roth's pioneering work on hydrogen sulfide has spawned Ikaria, a company exploring the molecule's potential to modulate the body's metabolism and perhaps one day turn hibernation into profitable clinical applications.
Charlie Schmidt
doi:10.1038/nbt0109-13
http://links.ealert.nature.com/ctt?kn=59&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
DATA PAGE
Compensation continues rise p14
Stacy Lawrence
doi:10.1038/nbt0109-14
http://links.ealert.nature.com/ctt?kn=26&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
NEWS FEATURE
Biotech's green gold? pp15 - 18
Algae have long been touted as a rich and ubiquitous source of renewable fuel but thus far have failed to be economically competitive with other sources of energy. Could new advances change that? Emily Waltz investigates.
Emily Waltz
doi:10.1038/nbt0109-15
http://links.ealert.nature.com/ctt?kn=104&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
----------------------
BIOENTREPRENEUR
----------------------
BUILDING A BUSINESS
Four steps to finding the right people
Of all the ingredients in a biotech start-up, getting the right people involved is most crucial. Here, Ian Brown, CEO of SDP Technology, provides pointers for putting together a successful business team.
Ian Brown
doi:10.1038/bioe.2008.11
http://links.ealert.nature.com/ctt?kn=70&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
----------------------
OPINION AND COMMENT
----------------------
CORRESPONDENCE
Industry and academia must avoid mismatching disclosures p21
Joseph P Hammang
doi:10.1038/nbt0109-21a
http://links.ealert.nature.com/ctt?kn=61&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
Stem cell transplants: the power of peer-to-peer pp21 - 22
Graham Creasy and Christopher Thomas Scott
doi:10.1038/nbt0109-21b
http://links.ealert.nature.com/ctt?kn=107&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
Is FAO selling biotech short on biofuels? pp22 - 23
Jonathan Gressel
doi:10.1038/nbt0109-22
http://links.ealert.nature.com/ctt?kn=90&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
Reply to Is FAO selling biotech short on biofuels? p23
Terri Raney
doi:10.1038/nbt0109-23
http://links.ealert.nature.com/ctt?kn=105&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
PRIME importance of pathology expertise pp24 - 25
Paul N Schofield et al.
doi:10.1038/nbt0109-24
http://links.ealert.nature.com/ctt?kn=127&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
COMMENTARY
Quality by design for biopharmaceuticals pp26 - 34
The US Food and Drug Administration's 'quality by design' approach is likely to transform the manufacture of biologics.
Anurag S Rathore and Helen Winkle
doi:10.1038/nbt0109-26
http://links.ealert.nature.com/ctt?kn=43&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
----------------------
BOOK REVIEW
----------------------
The house that George built p35
John Maraganore reviews Science Lessons: What the Business of Biotech Taught Me About Management
Gordon Binder and Philip Bashe
doi:10.1038/nbt0109-35
http://links.ealert.nature.com/ctt?kn=4&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
----------------------
FEATURES
----------------------
PATENTS
Patents versus patenting: implications of intellectual property protection for biological research pp36 - 40
A new survey shows scientists consider the proliferation of intellectual property protection to have a strongly negative effect on research.
Zhen Lei, Rakhi Juneja and Brian D Wright
doi:10.1038/nbt0109-36
http://links.ealert.nature.com/ctt?kn=57&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
Recent patent applications in antibody fragments p41
doi:10.1038/nbt0109-41
http://links.ealert.nature.com/ctt?kn=83&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
Crossing the Rubicon pp42 - 44
A viral vector injected intravenously in mice crosses the blood-brain barrier and transduces widespread regions of the brain and spinal cord.
Pedro R Lowenstein
doi:10.1038/nbt0109-42
http://links.ealert.nature.com/ctt?kn=67&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
Looking ahead in cancer stem cell research pp44 - 46
The history of the stem cell field offers pointers for future research on cancer stem cells.
John E Dick
doi:10.1038/nbt0109-44
http://links.ealert.nature.com/ctt?kn=52&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
GPS navigation of the protein-stability landscape pp46 - 48
Protein stability can now be studied in a high-throughput fashion at single-cell resolution.
Donald S Kirkpatrick and Vishva M Dixit
doi:10.1038/nbt0109-46
http://links.ealert.nature.com/ctt?kn=131&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
Research Highlights p49
doi:10.1038/nbt0109-49
http://links.ealert.nature.com/ctt?kn=69&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
----------------------
RESEARCH
----------------------
ANALYSIS
Understanding the physical properties that control protein crystallization by analysis of large-scale experimental data
W Nicholson Price II et al.
doi:10.1038/nbt.1514
Abstract: http://links.ealert.nature.com/ctt?kn=28&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=63&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
ARTICLES
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes pp59 - 65
Foust et al. describe a viral vector that crosses the blood-brain barrier, providing a non-invasive method for delivering therapeutic genes to the central nervous system. A single intravascular injection of AAV9 results in widespread transduction of astrocytes in adult mice and of astrocytes and neurons in neonatal mice.
Kevin D Foust et al.
doi:10.1038/nbt.1515
Abstract: http://links.ealert.nature.com/ctt?kn=25&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=35&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
PeakSeq enables systematic scoring of ChIP-seq experiments relative to controls pp66 - 75
Repetitive sequences and chromatin accessibility can confound scoring of chromatin immunoprecipitation data generated by high-throughput sequencing. Using data sets they produce for human RNA polymerase II and the transcription factor STAT1, Rozowsky et al. compensate for these biases by correcting for 'mappability' and normalizing the data against an input-DNA control.
Joel Rozowsky et al.
doi:10.1038/nbt.1518
Abstract: http://links.ealert.nature.com/ctt?kn=11&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=39&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
LETTERS
Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy pp77 - 83
Du et al. describe a bead-based method for high-throughput detection of phosphorylated tyrosine kinases and use it to profile 130 human cancer lines. They show that the tyrosine kinase SRC is frequently activated in glioblastoma cells and that a SRC inhibitor blocks the growth of glioblastoma tumors.
Jinyan Du et al.
doi:10.1038/nbt.1513
Abstract: http://links.ealert.nature.com/ctt?kn=2&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=15&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
Analysis of histone 2B-GFP retention reveals slowly cycling hematopoietic stem cells pp84 - 90
Foudi et al. report a method for monitoring the turnover of hematopoietic stem cells that has several advantages over BrdU labeling. Using drug-inducible expression of a histone 2B-GFP fusion protein, which permits a more sensitive analysis of division history, the authors detect hematopoietic stem cells that cycle at a very slow rate.
Adlen Foudi et al.
doi:10.1038/nbt.1517
Abstract: http://links.ealert.nature.com/ctt?kn=76&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=132&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
Characterization of human embryonic stem cells with features of neoplastic progression pp91 - 97
Werbowetski-Ogilvie et al. show that cultured human embryonic stem (hES) cells that appear normal may in fact be partially transformed. Two such lines are found to have aberrant growth and differentiation properties and submicroscopic chromosomal abnormalities.
Tamra E Werbowetski-Ogilvie et al.
doi:10.1038/nbt.1516
Abstract: http://links.ealert.nature.com/ctt?kn=50&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=123&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
----------------------
NATUREJOBS
----------------------
CAREERS AND RECRUITMENT
Executive compensation at private life science companies in troubled economic times pp98 - 99
The upward compensation trends reflected in our survey data, collected in the spring of 2008, stand in stark contrast to the economic conditions since October.
Bruce Rychlik and Mike DiPierro
doi:10.1038/nbt0109-98
http://links.ealert.nature.com/ctt?kn=100&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
PEOPLE
People p100
doi:10.1038/nbt0109-100
http://links.ealert.nature.com/ctt?kn=75&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
Cool new website, Hot science jobs!
Naturejobs is pleased to announce naturejobs.com has a new and improved look and functionality, making your Naturejobs online experience even better! Check out our redesign and find thousands of scientific vacancies, careers information, podcasts, advertising options and more!
=====================================================================
You have been sent this Table of Contents Alert because you have opted in to
receive it. You can change or discontinue your e-mail alerts at any time,
by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=17&m=30970530&r=MTYyMDUwNDY5NAS2&b=2&j=NDUxMzE4ODgS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2009 Nature Publishing Group
=====================================================================
